04.13.17
Phagelux, Inc., a biotechnology company focused on the development and commercialization of novel phage and lysin antibacterial products and solutions, has reached an agreement with Johnson & Johnson Consumer, Inc. to collaborate on the development of one or more skin care products. Under the terms of the agreement, Phagelux will be responsible for developing these products utilizing its patented or patent pending technologies and Johnson & Johnson Consumer, Inc. will provide specified financial support, access to certain skin care and formulation know-how, and support in protocol strategy and design.
The deal was facilitated by Johnson & Johnson Innovation.
Mark Engel, CEO of Phagelux said, "we believe this collaboration with Johnson & Johnson Consumer is an important step in our goal to create a globally relevant antibacterial company. Phagelux is now developing multiple products in multiple fields that will target either difficult to address bacteria or antibiotic resistant bacteria, often in collaboration with strong global partners such as Johnson & Johnson Consumer."
Phagelux is headquartered in Shanghai with laboratories in China and North America and it has manufacturing facilities in the US and China.
The deal was facilitated by Johnson & Johnson Innovation.
Mark Engel, CEO of Phagelux said, "we believe this collaboration with Johnson & Johnson Consumer is an important step in our goal to create a globally relevant antibacterial company. Phagelux is now developing multiple products in multiple fields that will target either difficult to address bacteria or antibiotic resistant bacteria, often in collaboration with strong global partners such as Johnson & Johnson Consumer."
Phagelux is headquartered in Shanghai with laboratories in China and North America and it has manufacturing facilities in the US and China.
